BioCentury

7:00 AM GMT, Jul 14, 2008
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Regulation

CDER’s safety chorus

FDA this month provided added color on the increased role and responsibilities of the Office of Surveillance and Epidemiology in working with the Office of New Drugs to address safety issues. There has been a significant shift toward giving an equal voice to agency staff across the disciplines.

Members of OND, which is responsible for drug reviews, and OSE, the agency’s drug safety office, have in the past found themselves at loggerheads over safety. A recent high-profile example is the controversy over the strength of evidence about the cardiovascular

Read the full 888 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.